See more : Booking Holdings Inc. (PCE1.DE) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaEngine, Inc. (4162.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaEngine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Data Image Corporation (3168.TWO) Income Statement Analysis – Financial Results
- eQ Oyj (EQV1V.HE) Income Statement Analysis – Financial Results
- Aurskog Sparebank (AURG.OL) Income Statement Analysis – Financial Results
- AV TECH Corporation (8072.TW) Income Statement Analysis – Financial Results
- Ujaas Energy Limited (UEL.NS) Income Statement Analysis – Financial Results
PharmaEngine, Inc. (4162.TWO)
About PharmaEngine, Inc.
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 767.67M | 654.38M | 654.84M | 1.06B | 314.04M | 293.43M | 853.68M | 1.13B | 507.24M | 228.99M | 37.40M | 184.03M | 320.05M | 0.00 | 0.00 |
| Cost of Revenue | 48.70M | 49.70M | 37.07M | 37.23M | 31.80M | 12.88M | 2.84M | 2.00M | 6.84M | 7.01M | 20.22M | 12.33M | 8.33M | 0.00 | 0.00 |
| Gross Profit | 718.97M | 604.68M | 617.76M | 1.02B | 282.24M | 280.55M | 850.84M | 1.13B | 500.41M | 221.98M | 17.18M | 171.70M | 311.73M | 0.00 | 0.00 |
| Gross Profit Ratio | 93.66% | 92.41% | 94.34% | 96.47% | 89.87% | 95.61% | 99.67% | 99.82% | 98.65% | 96.94% | 45.93% | 93.30% | 97.40% | 0.00% | 0.00% |
| Research & Development | 310.28M | 181.88M | 136.89M | 95.73M | 130.79M | 124.87M | 121.90M | 194.76M | 114.74M | 114.90M | 93.92M | 75.42M | 30.13M | 74.18M | 86.72M |
| General & Administrative | 92.97M | 94.95M | 81.67M | 76.23M | 83.73M | 77.40M | 75.75M | 102.50M | 58.34M | 36.53M | 62.74M | 46.65M | 39.28M | 17.78M | 19.53M |
| Selling & Marketing | 38.54M | 45.10M | 36.73M | 37.12M | 35.11M | 35.83M | 40.22M | 27.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.51M | 140.06M | 118.40M | 113.35M | 118.84M | 113.23M | 115.97M | 129.90M | 58.34M | 36.53M | 62.74M | 46.65M | 39.28M | 17.78M | 19.53M |
| Other Expenses | 0.00 | 84.23M | 167.50M | -98.39M | 17.17M | 121.33M | -115.98M | 29.78M | 79.67M | 53.77M | 21.64M | 803.00K | 5.17M | 43.37M | 7.33M |
| Operating Expenses | 441.79M | 321.94M | 255.29M | 209.07M | 249.63M | 238.11M | 237.87M | 324.66M | 173.08M | 151.43M | 156.66M | 122.07M | 69.41M | 91.96M | 106.25M |
| Cost & Expenses | 490.49M | 371.64M | 292.36M | 246.31M | 281.43M | 250.99M | 240.71M | 326.66M | 179.92M | 158.44M | 176.88M | 134.39M | 77.74M | 91.96M | 106.25M |
| Interest Income | 54.32M | 25.57M | 15.42M | 41.61M | 67.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.01M | 1.22M | 153.00K | 114.00K |
| Interest Expense | 310.00K | 77.00K | 212.00K | 443.00K | 112.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00K | 36.00K |
| Depreciation & Amortization | 9.02M | 8.61M | 10.26M | 12.56M | 6.71M | 2.93M | 3.05M | 3.00M | 1.63M | 280.00K | 338.00K | 530.00K | 658.00K | 1.60M | 1.98M |
| EBITDA | 347.31M | 401.15M | 555.87M | 765.48M | 56.49M | 166.70M | 616.02M | 811.12M | 328.96M | 70.83M | -139.15M | 50.06M | 262.61M | -46.53M | -96.69M |
| EBITDA Ratio | 45.24% | 61.30% | 84.85% | 72.49% | 17.99% | 15.46% | 72.16% | 71.48% | 64.85% | 30.93% | -372.05% | 27.26% | 82.05% | 0.00% | 0.00% |
| Operating Income | 277.18M | 392.55M | 545.39M | 752.92M | 49.78M | 42.44M | 612.97M | 808.12M | 327.33M | 70.55M | -139.48M | 49.63M | 242.32M | -91.96M | -106.25M |
| Operating Income Ratio | 36.11% | 59.99% | 83.29% | 71.30% | 15.85% | 14.46% | 71.80% | 71.21% | 64.53% | 30.81% | -372.95% | 26.97% | 75.71% | 0.00% | 0.00% |
| Total Other Income/Expenses | 60.79M | -84.00K | 3.00K | -57.23M | 17.06M | 121.33M | -115.98M | 29.78M | 79.67M | 53.77M | 21.64M | -645.00K | 19.63M | 43.81M | 7.54M |
| Income Before Tax | 337.97M | 392.47M | 545.40M | 752.48M | 49.67M | 163.77M | 496.99M | 837.91M | 406.99M | 124.32M | -117.85M | 48.99M | 261.95M | -48.15M | -98.70M |
| Income Before Tax Ratio | 44.03% | 59.97% | 83.29% | 71.26% | 15.82% | 55.81% | 58.22% | 73.84% | 80.24% | 54.29% | -315.10% | 26.62% | 81.85% | 0.00% | 0.00% |
| Income Tax Expense | 63.32M | 73.68M | 119.36M | 148.19M | 7.12M | 34.41M | 109.92M | 148.28M | 12.97M | 729.00K | 0.00 | 17.00K | -23.76M | 43.83M | 7.58M |
| Net Income | 274.65M | 318.78M | 426.03M | 604.28M | 42.55M | 129.36M | 387.06M | 689.63M | 394.02M | 123.59M | -117.85M | 48.99M | 285.71M | -48.15M | -98.70M |
| Net Income Ratio | 35.78% | 48.72% | 65.06% | 57.22% | 13.55% | 44.09% | 45.34% | 60.77% | 77.68% | 53.97% | -315.10% | 26.62% | 89.27% | 0.00% | 0.00% |
| EPS | 1.91 | 2.22 | 2.95 | 4.15 | 0.29 | 0.88 | 2.63 | 4.71 | 2.69 | 0.85 | -0.88 | 0.40 | 2.73 | -0.56 | -1.53 |
| EPS Diluted | 1.91 | 2.22 | 2.94 | 4.14 | 0.29 | 0.88 | 2.62 | 4.69 | 2.67 | 0.84 | -0.87 | 0.40 | 2.73 | -0.56 | -1.53 |
| Weighted Avg Shares Out | 143.61M | 143.60M | 144.54M | 145.62M | 145.69M | 147.12M | 147.11M | 146.52M | 146.51M | 144.78M | 134.68M | 121.15M | 104.50M | 86.24M | 64.67M |
| Weighted Avg Shares Out (Dil) | 143.74M | 143.70M | 144.74M | 145.90M | 145.73M | 147.60M | 147.76M | 147.14M | 147.75M | 147.19M | 135.17M | 123.68M | 104.50M | 86.24M | 64.67M |
Source: https://incomestatements.info
Category: Stock Reports